Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Time to clinical response, a proxy for hospital “discharge readiness,” was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodise, Thomas, Colman, Sam, Stein, Daniel S, Fitts, David, Goldberg, Lisa, Alexander, Elizabeth, Scoble, Patrick J, Schranz, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240345/
https://www.ncbi.nlm.nih.gov/pubmed/32462049
http://dx.doi.org/10.1093/ofid/ofaa145
Descripción
Sumario:Time to clinical response, a proxy for hospital “discharge readiness,” was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.

Ejemplares similares